Integrated Microfluidic LC-MS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Integrated Microfluidic LC-MS
The authors describe a new microfluidic-based workflow that integrates and automates glycan cleaveage, purification, and chromatographic separation onto a microfluidic liquid chromatography–mass spectrometry chip for MS detection.


Pharmaceutical Technology
Volume 34, pp. s32-s39

Conclusion

Until today, N-Linked glycan characterization workflows were tedious and time-consuming, making them unsuitable for real-time bioprocessing applications. A microfluidic LC–MS chip approach is described that integrates and automates all analysis steps: glycan cleavage, capture and purification, chromatographic separation, and MS detection. This approach reduces the previously lengthy incubation time for deglycosylation with PNGase F from many hours to 6 s. It eliminates reaction steps, including acidification, labeling, or derivatizing the free glycans used with traditional LC and MS approaches. Sample cleanup and labeling steps common to LIF detection, and acidification and desalting steps common to MALDI-TOF-MS are not needed. Rapid TOF-MS detection following deglycosylation makes it possible to measure -glycosylamine intermediates directly. Compared with measuring free reducing end glycans, this approach provided the advantages of simpler chromatographic peaks, isomer detection, and enhanced sensitivity.

In total, the integrated microfluidic LC–MS chip reduces analysis time from antibody injection to LC–MS results to 10 min and is completely automated once sample is introduced. It was also shown to separate isomers quickly and efficiently. The chip has the advantage of being able to characterize very complex glycan profiles. Low-level, unknown and nonfucosylated glycans were easily identified. Using a different LC–MS chip configuration, it is possible to analyze the deglycosylated antibody. The authors believe that this microfludic LC–MS chip-based workflow will facilitate fast and accurate glycan characterization in all stages of glycoprotein development and processing.

Maggie Bynum* is a scientist at Agilent Technologies' Agilent Laboratories, 5301 Stevens Creek Blvd, Santa Clara, CA 95051, tel. 408.553.3152, fax 408.553.2161,
. Tomasz Baginski is a scientist, and Rodney Keck is a senior scientist and senior group leader at Genentech. Kevin Killeen is a director at Agilent Technologies' Agilent Laboratories.

*To whom all correspondence should be addressed.

References

1. R.L. Shields et al., J. Biol. Chem. 277 (30), 26733–26740 (2002).

2. C.H. Chung et al., New Eng. J. Med. 358 (11), 1109–1117 ( 2008).

3. B.S. Kendrick et al., BioPharm Intl. 22 (8), 32–44 (2009).

4. P. Hermentin et al., Anal. Biochem, 203 (2), 281–289 (1992).

5. K.R. Anumula, Anal. Biochem. 283 (1), 17–26 (2000).

6. A. Guttman et al., Anal. Biochem. 233 (2), 234–242 (1996).

7. D.I. Papac et al., Glycobiology 8 (5), 445–454 (1998).

8. L.A. Gennaro and O. Salas-Solano, Anal. Chem. 80 (10), 3838–3845 (2008).

9. G.R. Guile et al., Anal. Biochem. 240 (2), 210–226 (1996).

10. M. Wuhrer et al., Mass Spec. Rev. 28 (2), 192–206 (2009).

11. M.R. Ninonuevo et. al., Agric. Food Chem. 54 (20), 7471–7480 (2006).

12. N. Tao et al, J. Dairy. Sci. 92 (7), 2991–3001 (2009).

13. M.A. Bynum et al., Anal. Chem. 81 (21), 8818–8825 (2009).

14. H. Yin et al., Anal. Chem, 77 (2), 527–533 (2005).

15. Consortium for Functional Glycomics, http://www.functionalglycomics.org/fg/site_guide/about.shtml, accessed Feb. 18, 2010.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here